Tech Company Financing Transactions
OncoMyx Therapeutics Funding Round
B Capital Group, Lumira Capital and Boehringer Ingelheim Venture Fund participated in a $50 million funding round for OncoMyx Therapeutics. This venture round closed on 12/9/2021.
Transaction Overview
Company Name
Announced On
12/9/2021
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Proceeds Purpose
With this financing, we plan to advance our lead multi-armed myxoma immunotherapy into clinical trials to demonstrate initial safety and efficacy of intravenous dosing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
445 N. 5th St.
Phoenix, AZ 85004
USA
Phoenix, AZ 85004
USA
Phone
Undisclosed
Website
Email Address
Overview
OncoMyx Therapeutics is developing oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Potts
Chief Operating Officer
Michael Wood
Chief Scientific Officer
Leslie Sharp
VP - R & D
Grant McFadden
Browse more venture capital transactions:
Prev: 12/9/2021: Afero venture capital transaction
Next: 12/9/2021: Loft Orbital venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs